Were Hedge Funds Right About Cara Therapeutics Inc (CARA)?
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Is NOMD Stock A Buy or Sell?
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Photo by IronHeart/Getty Images
At-home digital fitness studio Tempo has raised $220 million in its recently closed Series C funding round. SoftBank Vision Fund 2 led the round with additional participation from new investor Steadfast Capital Ventures and returning investors DCM, General Catalyst, Norwest Venture Partners, and Bling Capital.
Tempo plans to use the money to continue enhancing its artificial intelligence and 3D sensor tracking technology. The company’s flagship workout device scans users 30 times per second to guide users through the session while correcting their form when necessary.
Coming less than a year after its $60 million raise, Tempo now has nearly $300 million in funding to date.
CeQur, Medtronic, Roche, and Biocorp made moves in the diabetes market.
CeQur has raised $115 million in an oversubscribed equity financing. The Lucerne, Switzerland-based company has developed CeQur Simplicity, a wearable insulin delivery system.
Credit Suisse Entrepreneur Capital Ltd. and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Ypsomed Group, Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners.
Proceeds from the financing will be used to advance commercial plans for CeQur Simplicity, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing.